{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T14:56:54Z","timestamp":1761058614146},"reference-count":161,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2006,8,1]],"date-time":"2006-08-01T00:00:00Z","timestamp":1154390400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Immunology and Allergy Clinics of North America"],"published-print":{"date-parts":[[2006,8]]},"DOI":"10.1016\/j.iac.2006.05.009","type":"journal-article","created":{"date-parts":[[2007,1,10]],"date-time":"2007-01-10T15:09:23Z","timestamp":1168441763000},"page":"549-573","source":"Crossref","is-referenced-by-count":16,"title":["Treatment of Systemic Mastocytosis"],"prefix":"10.1016","volume":"26","author":[{"given":"Todd M.","family":"Wilson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dean D.","family":"Metcalfe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jamie","family":"Robyn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.iac.2006.05.009_bib1","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1007\/s00277-002-0575-z","article-title":"Mastocytosis: current concepts in diagnosis and treatment","volume":"81","author":"Escribano","year":"2002","journal-title":"Ann Hematol"},{"issue":"2","key":"10.1016\/j.iac.2006.05.009_bib2","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1093\/bja\/65.2.254","article-title":"Anaesthetic management of systemic mastocytosis","volume":"65","author":"Lerno","year":"1990","journal-title":"Br J Anaesth"},{"issue":"6","key":"10.1016\/j.iac.2006.05.009_bib3","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1016\/S0001-2092(07)66869-0","article-title":"Mastocytosis. Perioperative considerations","volume":"54","author":"Goins","year":"1991","journal-title":"AORN J"},{"issue":"3 Suppl","key":"10.1016\/j.iac.2006.05.009_bib4","article-title":"The treatment of mastocytosis: an overview","volume":"96","author":"Metcalfe","year":"1991","journal-title":"J Invest Dermatol"},{"issue":"4","key":"10.1016\/j.iac.2006.05.009_bib5","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/0190-9622(95)90336-4","article-title":"The mast cell and mast cell disease","volume":"32","author":"Longley","year":"1995","journal-title":"J Am Acad Dermatol"},{"issue":"1 Pt 1","key":"10.1016\/j.iac.2006.05.009_bib6","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S0091-6749(97)70314-2","article-title":"Fatal anaphylaxis after a yellow jacket sting, despite venom immunotherapy, in two patients with mastocytosis","volume":"99","author":"Oude Elberink","year":"1997","journal-title":"J Allergy Clin Immunol"},{"issue":"2 Suppl","key":"10.1016\/j.iac.2006.05.009_bib7","article-title":"Effect of superoxide dismutase on nitric oxide production by RAW264 macrophages","volume":"23","author":"Fricker","year":"1995","journal-title":"Biochem Soc Trans"},{"issue":"11","key":"10.1016\/j.iac.2006.05.009_bib8","first-page":"3047","article-title":"Cutaneous and systemic manifestations of mastocytosis","volume":"59","author":"Alto","year":"1999","journal-title":"Am Fam Physician"},{"issue":"1","key":"10.1016\/j.iac.2006.05.009_bib9","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S1081-1206(10)62662-2","article-title":"An unproven technique with potentially fatal outcome: provocation\/neutralization in a patient with systemic mastocytosis","volume":"82","author":"Teuber","year":"1999","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.iac.2006.05.009_bib10","first-page":"54","article-title":"Activation of human mast cells and basophils by general anaesthetic drugs","volume":"30","author":"Marone","year":"1992","journal-title":"Monogr Allergy"},{"key":"10.1016\/j.iac.2006.05.009_bib11","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1159\/000319299","article-title":"Mast cells and basophils in adverse reactions to drugs used during general anesthesia","volume":"62","author":"Stellato","year":"1995","journal-title":"Chem Immunol"},{"issue":"6","key":"10.1016\/j.iac.2006.05.009_bib12","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1097\/00000542-199106000-00016","article-title":"Heterogeneity of human mast cells and basophils in response to muscle relaxants","volume":"74","author":"Stellato C de","year":"1991","journal-title":"Anesthesiology"},{"issue":"9","key":"10.1016\/j.iac.2006.05.009_bib13","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1213\/00000539-198009000-00015","article-title":"General anesthesia in a child with urticaria pigmentosa","volume":"59","author":"Coleman","year":"1980","journal-title":"Anesth Analg"},{"issue":"5","key":"10.1016\/j.iac.2006.05.009_bib14","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1097\/00000658-198305000-00002","article-title":"Hazards in operative management of patients with systemic mastocytosis","volume":"197","author":"Scott","year":"1983","journal-title":"Ann Surg"},{"issue":"2","key":"10.1016\/j.iac.2006.05.009_bib15","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/0952-8180(90)90063-9","article-title":"Urticaria pigmentosa: an anesthetic challenge","volume":"2","author":"Greenblatt","year":"1990","journal-title":"J Clin Anesth"},{"issue":"8","key":"10.1016\/j.iac.2006.05.009_bib16","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1046\/j.1365-2044.1998.00536.x","article-title":"Systemic mastocytosis presenting as profound cardiovascular collapse during anaesthesia","volume":"53","author":"Vaughan","year":"1998","journal-title":"Anaesthesia"},{"issue":"2","key":"10.1016\/j.iac.2006.05.009_bib17","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1213\/00000539-199802000-00044","article-title":"Anesthesia in a patient with malignant systemic mastocytosis using a total intravenous anesthetic technique","volume":"86","author":"Borgeat","year":"1998","journal-title":"Anesth Analg"},{"issue":"2","key":"10.1016\/j.iac.2006.05.009_bib18","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/0091-6749(83)90098-2","article-title":"Intervention with epinephrine in hypotension associated with mastocytosis","volume":"71","author":"Turk","year":"1983","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"10.1016\/j.iac.2006.05.009_bib19","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1093\/bja\/80.1.26","article-title":"Mast cell tryptase in anaesthetic anaphylactoid reactions","volume":"80","author":"Fisher","year":"1998","journal-title":"Br J Anaesth"},{"issue":"3 Pt 1","key":"10.1016\/j.iac.2006.05.009_bib20","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/0091-6749(94)90213-5","article-title":"Rush Hymenoptera venom immunotherapy: successful treatment in a patient with systemic mast cell disease","volume":"94","author":"Engler","year":"1994","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"10.1016\/j.iac.2006.05.009_bib21","first-page":"52","article-title":"[Systemic mastocytosis: a review of the literature and of the cases in Reggio Emilia from 1986 to 1994.]","volume":"11","author":"D'Inca","year":"1996","journal-title":"Ann Ital Med Int"},{"issue":"3","key":"10.1016\/j.iac.2006.05.009_bib22","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/S0889-8588(05)70301-4","article-title":"Treatment of systemic mast cell disorders","volume":"14","author":"Worobec","year":"2000","journal-title":"Hematol Oncol Clin North Am"},{"issue":"9","key":"10.1016\/j.iac.2006.05.009_bib23","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1056\/NEJM199202273260912","article-title":"Systemic mastocytosis","volume":"326","author":"Austen","year":"1992","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.iac.2006.05.009_bib24","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1159\/000048188","article-title":"Mastocytosis: mediator-related signs and symptoms","volume":"127","author":"Castells","year":"2002","journal-title":"Int Arch Allergy Immunol"},{"issue":"2 Suppl","key":"10.1016\/j.iac.2006.05.009_bib25","doi-asserted-by":"crossref","first-page":"S486","DOI":"10.1067\/mai.2003.120","article-title":"4. IgE, mast cells, basophils, and eosinophils","volume":"111","author":"Prussin","year":"2003","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"10.1016\/j.iac.2006.05.009_bib26","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1159\/000048189","article-title":"Mastocytosis: current treatment concepts","volume":"127","author":"Worobec","year":"2002","journal-title":"Int Arch Allergy Immunol"},{"issue":"7","key":"10.1016\/j.iac.2006.05.009_bib27","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/S0145-2126(01)00039-X","article-title":"Treatment of mastocytosis: pharmacologic basis and current concepts","volume":"25","author":"Marone","year":"2001","journal-title":"Leuk Res"},{"key":"10.1016\/j.iac.2006.05.009_bib28","series-title":"Allergy","first-page":"854","article-title":"Systemic mastocytosis","author":"Bianchine","year":"1997"},{"issue":"Suppl","key":"10.1016\/j.iac.2006.05.009_bib29","doi-asserted-by":"crossref","first-page":"1S","DOI":"10.1111\/1523-1747.ep12468869","article-title":"Clinical advances in mastocytosis: an interdisciplinary roundtable discussion","volume":"96","author":"Metcalfe","year":"1991","journal-title":"J Invest Dermatol"},{"issue":"2","key":"10.1016\/j.iac.2006.05.009_bib30","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1159\/000247526","article-title":"Systemic mastocytosis treated with histamine H1 and H2 receptor antagonists","volume":"184","author":"Gasior-Chrzan","year":"1992","journal-title":"Dermatology"},{"issue":"1","key":"10.1016\/j.iac.2006.05.009_bib31","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1001\/archderm.1985.01660010119035","article-title":"Congenital bullous urticaria pigmentosa. Treatment with concomitant use of H1- and H2-receptor antagonists","volume":"121","author":"Fenske","year":"1985","journal-title":"Arch Dermatol"},{"issue":"6 Pt 2","key":"10.1016\/j.iac.2006.05.009_bib32","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1016\/S0091-6749(97)70001-0","article-title":"Heterogeneity of mast cells in mastocytosis and inhibitory effect of ketotifen and ranitidine on indolent systemic mastocytosis","volume":"100","author":"Kurosawa","year":"1997","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"10.1016\/j.iac.2006.05.009_bib33","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/0002-9343(85)90454-1","article-title":"Comparison of the therapeutic efficacy of cromolyn sodium with that of combined chlorpheniramine and cimetidine in systemic mastocytosis. Results of a double-blind clinical trial","volume":"78","author":"Frieri","year":"1985","journal-title":"Am J Med"},{"issue":"3","key":"10.1016\/j.iac.2006.05.009_bib34","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1177\/106002808101500303","article-title":"Cimetidine in systemic mastocytosis","volume":"15","author":"Berg","year":"1981","journal-title":"Drug Intell Clin Pharm"},{"issue":"5","key":"10.1016\/j.iac.2006.05.009_bib35","doi-asserted-by":"crossref","first-page":"769","DOI":"10.7326\/0003-4819-90-5-769","article-title":"Effect of cimetidine on gastric hypersecretion and diarrhea in systemic mastocytosis","volume":"90","author":"Hirschowitz","year":"1979","journal-title":"Ann Intern Med"},{"issue":"6","key":"10.1016\/j.iac.2006.05.009_bib36","first-page":"485","article-title":"Long-term treatment of systemic mastocytosis with histamine H2 receptor antagonists","volume":"74","author":"Johnson","year":"1980","journal-title":"Am J Gastroenterol"},{"issue":"3","key":"10.1016\/j.iac.2006.05.009_bib37","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/S0889-8588(05)70298-7","article-title":"Gastrointestinal abnormalities and involvement in systemic mastocytosis","volume":"14","author":"Jensen","year":"2000","journal-title":"Hematol Oncol Clin North Am"},{"issue":"2","key":"10.1016\/j.iac.2006.05.009_bib38","first-page":"133","article-title":"Malabsorption and gastric hyperacidity in systemic mastocytosis. Results of cimetidine therapy","volume":"74","author":"Bredfeldt","year":"1980","journal-title":"Am J Gastroenterol"},{"issue":"4","key":"10.1016\/j.iac.2006.05.009_bib39","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/0002-9343(80)90476-3","article-title":"The effect of cimetidine and propantheline on the symptoms of a patient with systemic mastocytosis","volume":"69","author":"Achord","year":"1980","journal-title":"Am J Med"},{"issue":"2","key":"10.1016\/j.iac.2006.05.009_bib40","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1159\/000206179","article-title":"Disodium cromoglycate in the treatment of systemic mastocytosis involving only bone 4","volume":"74","author":"Alexander","year":"1985","journal-title":"Acta Haematol"},{"issue":"5","key":"10.1016\/j.iac.2006.05.009_bib41","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/0091-6749(90)90067-E","article-title":"Cromolyn sodium in the management of systemic mastocytosis","volume":"85","author":"Horan","year":"1990","journal-title":"J Allergy Clin Immunol"},{"issue":"9","key":"10.1016\/j.iac.2006.05.009_bib42","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1056\/NEJM197908303010903","article-title":"Oral disodium cromoglycate in the treatment of systemic mastocytosis","volume":"301","author":"Soter","year":"1979","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.iac.2006.05.009_bib43","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1097\/00000441-199506000-00007","article-title":"Southwestern Internal Medicine Conference: mastocytosis: developments during the past decade","volume":"309","author":"Gruchalla","year":"1995","journal-title":"Am J Med Sci"},{"issue":"2","key":"10.1016\/j.iac.2006.05.009_bib44","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1111\/j.1365-2222.1984.tb02646.x","article-title":"Systemic mastocytosis in a 5-year-old child: successful treatment with disodium cromoglycate","volume":"14","author":"Businco","year":"1984","journal-title":"Clin Allergy"},{"issue":"5","key":"10.1016\/j.iac.2006.05.009_bib45","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1111\/j.1365-2133.1981.tb00800.x","article-title":"Urticaria pigmentosa: clinical picture and response to oral disodium cromoglycate","volume":"105","author":"Czarnetzki","year":"1981","journal-title":"Br J Dermatol"},{"issue":"3","key":"10.1016\/j.iac.2006.05.009_bib46","first-page":"197","article-title":"Pediatric mastocytosis","volume":"73","author":"Kettelhut","year":"1994","journal-title":"Ann Allergy"},{"issue":"3 Suppl","key":"10.1016\/j.iac.2006.05.009_bib47","article-title":"Pediatric mastocytosis","volume":"96","author":"Kettelhut","year":"1991","journal-title":"J Invest Dermatol"},{"issue":"2","key":"10.1016\/j.iac.2006.05.009_bib48","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s001050050559","article-title":"[Bullous mastocytosis in a child.]","volume":"48","author":"Haustein","year":"1997","journal-title":"Hautarzt"},{"issue":"3","key":"10.1016\/j.iac.2006.05.009_bib49","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/S0190-9622(83)70140-4","article-title":"Treatment of bullous mastocytosis with disodium cromoglycate","volume":"9","author":"Welch","year":"1983","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"10.1016\/j.iac.2006.05.009_bib50","first-page":"358","article-title":"Bullous urticaria pigmentosa","volume":"58","author":"Leaf","year":"1996","journal-title":"Cutis"},{"issue":"1","key":"10.1016\/j.iac.2006.05.009_bib51","first-page":"54","article-title":"Mastocytosis with malabsorption, myelofibrosis, and massive ascites","volume":"82","author":"Reisberg","year":"1987","journal-title":"Am J Gastroenterol"},{"issue":"4","key":"10.1016\/j.iac.2006.05.009_bib52","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1007\/BF02592695","article-title":"Clinical advances in mastocytosis","volume":"25","author":"Genovese","year":"1995","journal-title":"Int J Clin Lab Res"},{"key":"10.1016\/j.iac.2006.05.009_bib53","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000319293","article-title":"Biology, diagnosis and therapy of mastocytosis","volume":"62","author":"Marone","year":"1995","journal-title":"Chem Immunol"},{"issue":"2","key":"10.1016\/j.iac.2006.05.009_bib54","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/BF01297110","article-title":"Intractable ascites in systemic mastocytosis treated by portal diversion","volume":"32","author":"Bonnet","year":"1987","journal-title":"Dig Dis Sci"},{"issue":"10","key":"10.1016\/j.iac.2006.05.009_bib55","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1007\/BF01959789","article-title":"A fatal case of portal hypertension complicating systemic mastocytosis in an adolescent","volume":"154","author":"Fonga-Djimi","year":"1995","journal-title":"Eur J Pediatr"},{"issue":"7","key":"10.1016\/j.iac.2006.05.009_bib56","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1172\/JCI119336","article-title":"Glucocorticoids decrease tissue mast cell number by reducing the production of the c-kit ligand, stem cell factor, by resident cells: in vitro and in vivo evidence in murine systems","volume":"99","author":"Finotto","year":"1997","journal-title":"J Clin Invest"},{"issue":"12","key":"10.1016\/j.iac.2006.05.009_bib57","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1001\/archderm.1985.01660120042017","article-title":"Treatment of urticaria pigmentosa with corticosteroids","volume":"121","author":"Barton","year":"1985","journal-title":"Arch Dermatol"},{"issue":"4","key":"10.1016\/j.iac.2006.05.009_bib58","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.4049\/jimmunol.135.4.2368","article-title":"Cutaneous mast cell depletion results from topical corticosteroid usage","volume":"135","author":"Lavker","year":"1985","journal-title":"J Immunol"},{"issue":"2","key":"10.1016\/j.iac.2006.05.009_bib59","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1001\/archderm.1991.01680020059005","article-title":"Urticaria pigmentosa. Systemic evaluation and successful treatment with topical steroids","volume":"127","author":"Guzzo","year":"1991","journal-title":"Arch Dermatol"},{"issue":"4","key":"10.1016\/j.iac.2006.05.009_bib60","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1097\/00000421-199408000-00009","article-title":"Radiotherapy of refractory bone pain due to systemic mast cell disease","volume":"17","author":"Johnstone","year":"1994","journal-title":"Am J Clin Oncol"},{"issue":"3","key":"10.1016\/j.iac.2006.05.009_bib61","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1093\/rheumatology\/36.3.393","article-title":"The effect of pamidronate on lumbar spine bone density and pain in osteoporosis secondary to systemic mastocytosis","volume":"36","author":"Marshall","year":"1997","journal-title":"Br J Rheumatol"},{"issue":"3","key":"10.1016\/j.iac.2006.05.009_bib62","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/8756-3282(87)90014-7","article-title":"Osteopenia in systemic mastocytosis: natural history and responses to treatment with inhibitors of bone resorption","volume":"8","author":"Cundy","year":"1987","journal-title":"Bone"},{"issue":"4","key":"10.1016\/j.iac.2006.05.009_bib63","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1097\/00000421-199208000-00013","article-title":"Radiation therapy in a case of systemic mastocytosis: evaluation of histamine levels and mucosal effects","volume":"15","author":"Janjan","year":"1992","journal-title":"Am J Clin Oncol"},{"issue":"12","key":"10.1016\/j.iac.2006.05.009_bib64","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1001\/archderm.1996.03890360013002","article-title":"Diffuse cutaneous mastocytosis. Treatment with oral psoralen plus UVA","volume":"132","author":"Mackey","year":"1996","journal-title":"Arch Dermatol"},{"issue":"1","key":"10.1016\/j.iac.2006.05.009_bib65","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1159\/000245681","article-title":"Short- and long-term effectiveness of oral and bath PUVA therapy in urticaria pigmentosa and systemic mastocytosis","volume":"195","author":"Godt","year":"1997","journal-title":"Dermatology"},{"issue":"6","key":"10.1016\/j.iac.2006.05.009_bib66","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1111\/j.1365-2133.1978.tb03592.x","article-title":"PUVA-treatment of urticaria pigmentosa","volume":"98","author":"Christophers","year":"1978","journal-title":"Br J Dermatol"},{"issue":"2","key":"10.1016\/j.iac.2006.05.009_bib67","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/BF00414106","article-title":"Phototherapy of urticaria pigmentosa: clinical response and changes of cutaneous reactivity, histamine and chemotactic leukotrienes","volume":"277","author":"Czarnetzki","year":"1985","journal-title":"Arch Dermatol Res"},{"issue":"3","key":"10.1016\/j.iac.2006.05.009_bib68","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1111\/1523-1747.ep12263520","article-title":"Response of cutaneous mast cells to PUVA in patients with urticaria pigmentosa: histomorphometric, ultrastructural, and biochemical investigations","volume":"83","author":"Kolde","year":"1984","journal-title":"J Invest Dermatol"},{"issue":"4","key":"10.1016\/j.iac.2006.05.009_bib69","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1111\/j.1525-1470.1990.tb01020.x","article-title":"Photochemotherapy of dominant, diffuse, cutaneous mastocytosis","volume":"7","author":"Smith","year":"1990","journal-title":"Pediatr Dermatol"},{"issue":"8993","key":"10.1016\/j.iac.2006.05.009_bib70","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/S0140-6736(96)91600-1","article-title":"High-dose UVA1 for urticaria pigmentosa","volume":"347","author":"Stege","year":"1996","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.iac.2006.05.009_bib71","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1111\/j.1365-2133.1983.tb03994.x","article-title":"Photochemotherapy (PUVA) in the treatment of urticaria pigmentosa","volume":"109","author":"Vella Briffa","year":"1983","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.iac.2006.05.009_bib72","series-title":"Middleton's allergy: principles and practice; mastocytosis syndromes, vol. 2","author":"Metcalfe","year":"2003"},{"issue":"6","key":"10.1016\/j.iac.2006.05.009_bib73","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1111\/j.1365-2230.1989.tb02602.x","article-title":"Cutaneous and ocular side-effects of PUVA photochemotherapy\u2014a 10-year follow-up study","volume":"14","author":"Abdullah","year":"1989","journal-title":"Clin Exp Dermatol"},{"issue":"4","key":"10.1016\/j.iac.2006.05.009_bib74","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1067\/S0190-9622(03)01483-X","article-title":"Medium- versus high-dose ultraviolet A1 therapy for urticaria pigmentosa: a pilot study","volume":"49","author":"Gobello","year":"2003","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.iac.2006.05.009_bib75","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1111\/j.1525-1470.1989.tb01009.x","article-title":"Shock in an infant with bullous mastocytosis","volume":"6","author":"Poterack","year":"1989","journal-title":"Pediatr Dermatol"},{"issue":"4","key":"10.1016\/j.iac.2006.05.009_bib76","first-page":"356","article-title":"Mastocytosis\/vasodilatory shock in a 25-year-old woman","volume":"15","author":"Walton","year":"1989","journal-title":"J Emerg Nurs"},{"issue":"3 Suppl","key":"10.1016\/j.iac.2006.05.009_bib77","article-title":"Systemic mastocytosis: retrospective review of a decade's clinical experience at the Brigham and Women's Hospital","volume":"96","author":"Horan","year":"1991","journal-title":"J Invest Dermatol"},{"issue":"4","key":"10.1016\/j.iac.2006.05.009_bib78","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0300-2977(96)00089-7","article-title":"Shock of unknown origin\u2014think of mastocytosis","volume":"50","author":"Gonera","year":"1997","journal-title":"Neth J Med"},{"issue":"6","key":"10.1016\/j.iac.2006.05.009_bib79","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1093\/bja\/65.6.833","article-title":"Massive histamine release in a patient with systemic mastocytosis","volume":"65","author":"Desborough","year":"1990","journal-title":"Br J Anaesth"},{"key":"10.1016\/j.iac.2006.05.009_bib80","series-title":"Current therapy in allergy, immunology and rheumatology","author":"Worobec","year":"1996"},{"issue":"1","key":"10.1016\/j.iac.2006.05.009_bib81","first-page":"1","article-title":"Systemic mastocytosis: management of an unusual case with histamine (H1 and H2) antagonists and cyclooxygenase inhibition","volume":"10","author":"Crawhall","year":"1987","journal-title":"Clin Invest Med"},{"issue":"5","key":"10.1016\/j.iac.2006.05.009_bib82","doi-asserted-by":"crossref","first-page":"481","DOI":"10.4065\/70.5.481","article-title":"Aspirin idiosyncrasy in systemic mast cell disease: a new look at mediator release during aspirin desensitization","volume":"70","author":"Butterfield","year":"1995","journal-title":"Mayo Clin Proc"},{"issue":"7","key":"10.1016\/j.iac.2006.05.009_bib83","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/S0145-2126(02)00168-6","article-title":"Aggressive systemic mastocytosis and related mast cell disorders: current treatment options and proposed response criteria","volume":"27","author":"Valent","year":"2003","journal-title":"Leuk Res"},{"issue":"5","key":"10.1016\/j.iac.2006.05.009_bib84","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1046\/j.1365-2141.2003.04575.x","article-title":"Diagnosis and treatment of systemic mastocytosis: state of the art","volume":"122","author":"Valent","year":"2003","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.iac.2006.05.009_bib85","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1080\/10428190400010775","article-title":"Mastocytosis: pathology, genetics, and current options for therapy","volume":"46","author":"Valent","year":"2005","journal-title":"Leuk Lymphoma"},{"issue":"6","key":"10.1016\/j.iac.2006.05.009_bib86","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1089\/107999003766628124","article-title":"Interferons and apoptosis","volume":"23","author":"Clemens","year":"2003","journal-title":"J Interferon Cytokine Res"},{"issue":"10","key":"10.1016\/j.iac.2006.05.009_bib87","doi-asserted-by":"crossref","first-page":"3074","DOI":"10.1182\/blood.V98.10.3074","article-title":"Chronic myeloid leukemia and interferon-alpha: a study of complete cytogenetic responders","volume":"98","author":"Bonifazi","year":"2001","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.iac.2006.05.009_bib88","doi-asserted-by":"crossref","first-page":"4064","DOI":"10.1182\/blood.V84.12.4064.bloodjournal84124064","article-title":"Randomized comparison of interferon-alpha with busulfan and hydroxyurea in chronic myelogenous leukemia. The German CML Study Group","volume":"84","author":"Hehlmann","year":"1994","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.iac.2006.05.009_bib89","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1182\/blood.V86.3.906.906","article-title":"A randomized trial comparing interferon-alpha with busulfan for newly diagnosed chronic myelogenous leukemia in chronic phase","volume":"86","author":"Ohnishi","year":"1995","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.iac.2006.05.009_bib90","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/S0145-2126(98)00082-4","article-title":"A long term follow-up of a randomized trial comparing interferon-alpha with busulfan for chronic myelogenous leukemia. The Kouseisho Leukemia Study Group","volume":"22","author":"Ohnishi","year":"1998","journal-title":"Leuk Res"},{"issue":"9","key":"10.1016\/j.iac.2006.05.009_bib91","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1056\/NEJM199202273260907","article-title":"Response to interferon alfa-2b in a patient with systemic mastocytosis","volume":"326","author":"Kluin-Nelemans","year":"1992","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.iac.2006.05.009_bib92","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1046\/j.1365-2133.1998.02131.x","article-title":"Response of severe systemic mastocytosis to interferon alpha","volume":"138","author":"Butterfield","year":"1998","journal-title":"Br J Dermatol"},{"issue":"3","key":"10.1016\/j.iac.2006.05.009_bib93","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/S0190-9622(08)81953-6","article-title":"Interferon treatment of patients with chronic urticaria and mastocytosis","volume":"30","author":"Czarnetzki","year":"1994","journal-title":"J Am Acad Dermatol"},{"issue":"8","key":"10.1016\/j.iac.2006.05.009_bib94","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1111\/j.1365-2362.1995.tb01754.x","article-title":"Treatment of systemic mastocytosis with interferon-gamma: failure after appearance of anti-IFN-gamma antibodies","volume":"25","author":"Fiehn","year":"1995","journal-title":"Eur J Clin Invest"},{"issue":"3","key":"10.1016\/j.iac.2006.05.009_bib95","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1002\/ajh.20211","article-title":"Management of patients with systemic mastocytosis: review of M.D. Anderson Cancer Center experience","volume":"77","author":"Hennessy","year":"2004","journal-title":"Am J Hematol"},{"issue":"6","key":"10.1016\/j.iac.2006.05.009_bib96","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1111\/j.1365-2796.1997.tb00013.x","article-title":"Clinical stable systemic mastocytosis with interferon alpha-2b therapy","volume":"241","author":"Hubner","year":"1997","journal-title":"J Intern Med"},{"issue":"10","key":"10.1016\/j.iac.2006.05.009_bib97","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1007\/s002770050604","article-title":"IFNalpha treatment in systemic mastocytosis","volume":"78","author":"Lehmann","year":"1999","journal-title":"Ann Hematol"},{"issue":"1","key":"10.1016\/j.iac.2006.05.009_bib98","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1002\/ajh.2830470121","article-title":"Long-term response to interferon-alpha in a patient with systemic mastocytosis and chronic myelomonocytic leukemia","volume":"47","author":"Pulik","year":"1994","journal-title":"Am J Hematol"},{"issue":"5","key":"10.1016\/j.iac.2006.05.009_bib99","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.patbio.2004.04.012","article-title":"Interest of interferon alpha in systemic mastocytosis. The French experience and review of the literature","volume":"52","author":"Simon","year":"2004","journal-title":"Pathol Biol (Paris)"},{"issue":"1","key":"10.1016\/j.iac.2006.05.009_bib100","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/BF00663015","article-title":"Successful treatment of osteoporosis in systemic mastocytosis with interferon alpha-2b","volume":"72","author":"Weide","year":"1996","journal-title":"Ann Hematol"},{"issue":"5\u20136","key":"10.1016\/j.iac.2006.05.009_bib101","doi-asserted-by":"crossref","first-page":"501","DOI":"10.3109\/10428199609054789","article-title":"Treatment of three patients with systemic mastocytosis with interferon alpha-2b","volume":"22","author":"Worobec","year":"1996","journal-title":"Leuk Lymphoma"},{"issue":"5 Pt 2","key":"10.1016\/j.iac.2006.05.009_bib102","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/0190-9622(95)91545-1","article-title":"Systemic mastocytosis associated with chronic myelomonocytic leukemia: clinical features and response to interferon alfa therapy","volume":"32","author":"Petit","year":"1995","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.iac.2006.05.009_bib103","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1111\/j.1365-2133.1995.tb02499.x","article-title":"Treatment of urticaria pigmentosa using interferon alpha","volume":"133","author":"Kolde","year":"1995","journal-title":"Br J Dermatol"},{"issue":"3","key":"10.1016\/j.iac.2006.05.009_bib104","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0145-2126(03)00259-5","article-title":"Response to therapy with interferon alpha-2b and prednisolone in aggressive systemic mastocytosis: report of five cases and review of the literature","volume":"28","author":"Hauswirth","year":"2004","journal-title":"Leuk Res"},{"issue":"1","key":"10.1016\/j.iac.2006.05.009_bib105","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/S1521-6926(02)00089-0","article-title":"Cladribine in the treatment of hairy-cell leukaemia","volume":"16","author":"Goodman","year":"2003","journal-title":"Best Pract Res Clin Haematol"},{"issue":"5","key":"10.1016\/j.iac.2006.05.009_bib106","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1172\/JCI114865","article-title":"Potent toxicity of 2-chlorodeoxyadenosine toward human monocytes in vitro and in vivo. A novel approach to immunosuppressive therapy","volume":"86","author":"Carrera","year":"1990","journal-title":"J Clin Invest"},{"issue":"7","key":"10.1016\/j.iac.2006.05.009_bib107","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1182\/blood.V94.7.2333.419k30_2333_2342","article-title":"Demonstration that human mast cells arise from a progenitor cell population that is CD34(+), c-kit(+), and expresses aminopeptidase N (CD13)","volume":"94","author":"Kirshenbaum","year":"1999","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.iac.2006.05.009_bib108","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1056\/NEJM200101253440415","article-title":"Treatment of systemic mast-cell disease with cladribine","volume":"344","author":"Tefferi","year":"2001","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.iac.2006.05.009_bib109","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1016\/S0145-2126(02)00073-5","article-title":"Cladribine induces immunophenotypical changes in bone marrow mast cells from mastocytosis. Report of a case of mastocytosis associated with a lymphoplasmacytic lymphoma","volume":"26","author":"Escribano","year":"2002","journal-title":"Leuk Res"},{"issue":"13","key":"10.1016\/j.iac.2006.05.009_bib110","doi-asserted-by":"crossref","first-page":"4270","DOI":"10.1182\/blood-2003-05-1699","article-title":"Cladribine therapy for systemic mastocytosis","volume":"102","author":"Kluin-Nelemans","year":"2003","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.iac.2006.05.009_bib111","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S0145-2126(03)00185-1","article-title":"Treatment of systemic mast cell disease with 2-chlorodeoxyadenosine","volume":"28","author":"Pardanani","year":"2004","journal-title":"Leuk Res"},{"issue":"10","key":"10.1016\/j.iac.2006.05.009_bib112","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1007\/s00277-005-1057-x","article-title":"Cladribine therapy in a patient with an aleukemic subvariant of mast cell leukemia","volume":"84","author":"Penack","year":"2005","journal-title":"Ann Hematol"},{"key":"10.1016\/j.iac.2006.05.009_bib113","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0065-230X(04)91001-9","article-title":"Imatinib as a paradigm of targeted therapies","volume":"91","author":"Druker","year":"2004","journal-title":"Adv Cancer Res"},{"issue":"8","key":"10.1016\/j.iac.2006.05.009_bib114","doi-asserted-by":"crossref","first-page":"2929","DOI":"10.1182\/blood-2003-10-3443","article-title":"Serum KIT and KIT ligand levels in patients with gastrointestinal stromal tumors treated with imatinib","volume":"103","author":"Bono","year":"2004","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.iac.2006.05.009_bib115","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1097\/00062752-200401000-00008","article-title":"The FIP1L1-PDGFRalpha kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia","volume":"11","author":"Cools","year":"2004","journal-title":"Curr Opin Hematol"},{"issue":"1","key":"10.1016\/j.iac.2006.05.009_bib116","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1081\/CNV-120027585","article-title":"Biology of gastrointestinal stromal tumors: KIT mutations and beyond","volume":"22","author":"Duensing","year":"2004","journal-title":"Cancer Invest"},{"issue":"12","key":"10.1016\/j.iac.2006.05.009_bib117","doi-asserted-by":"crossref","first-page":"4660","DOI":"10.1182\/blood-2003-01-0006","article-title":"Elevated serum tryptase levels identify a subset of patients with a myeloproliferative variant of idiopathic hypereosinophilic syndrome associated with tissue fibrosis, poor prognosis, and imatinib responsiveness","volume":"101","author":"Klion","year":"2003","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.iac.2006.05.009_bib118","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1182\/blood-2003-08-2798","article-title":"Molecular remission and reversal of myelofibrosis in response to imatinib mesylate treatment in patients with the myeloproliferative variant of hypereosinophilic syndrome","volume":"103","author":"Klion","year":"2004","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.iac.2006.05.009_bib119","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/S0301-472X(03)00112-7","article-title":"Effects of tyrosine kinase inhibitor STI571 on human mast cells bearing wild-type or mutated c-kit","volume":"31","author":"Akin","year":"2003","journal-title":"Exp Hematol"},{"issue":"5","key":"10.1016\/j.iac.2006.05.009_bib120","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1182\/blood.V99.5.1741","article-title":"The c-KIT mutation causing human mastocytosis is resistant to STI571 and other KIT kinase inhibitors; kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wild-type kinases and those with regulatory-type mutations","volume":"99","author":"Ma","year":"2002","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.iac.2006.05.009_bib121","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1038\/sj.onc.1206120","article-title":"Effect of tyrosine kinase inhibitor STI571 on the kinase activity of wild-type and various mutated c-kit receptors found in mast cell neoplasms","volume":"22","author":"Zermati","year":"2003","journal-title":"Oncogene"},{"issue":"12","key":"10.1016\/j.iac.2006.05.009_bib122","first-page":"1115","article-title":"Juxtamembrane mutant V560GKit is more sensitive to imatinib (STI571) compared with wild-type c-kit whereas the kinase domain mutant D816VKit is resistant","volume":"1","author":"Frost","year":"2002","journal-title":"Mol Cancer Ther"},{"issue":"4","key":"10.1016\/j.iac.2006.05.009_bib123","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.leukres.2003.09.001","article-title":"Inefficacy of imatinib-mesylate in sporadic, aggressive systemic mastocytosis","volume":"28","author":"Musto","year":"2004","journal-title":"Leuk Res"},{"issue":"9383","key":"10.1016\/j.iac.2006.05.009_bib124","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/S0140-6736(03)14115-3","article-title":"Imatinib for systemic mast-cell disease","volume":"362","author":"Pardanani","year":"2003","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.iac.2006.05.009_bib125","doi-asserted-by":"crossref","first-page":"3093","DOI":"10.1182\/blood-2003-05-1627","article-title":"CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy","volume":"102","author":"Pardanani","year":"2003","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.iac.2006.05.009_bib126","doi-asserted-by":"crossref","first-page":"3222","DOI":"10.1182\/blood-2003-11-3816","article-title":"A novel form of mastocytosis associated with a transmembrane c-kit mutation and response to imatinib","volume":"103","author":"Akin","year":"2004","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.iac.2006.05.009_bib127","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/S0025-6196(12)62636-6","article-title":"Mast cell leukemia: report of a case and review of the literature","volume":"61","author":"Travis","year":"1986","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.iac.2006.05.009_bib128","series-title":"Mastocytosis. World Health Organization classification of tumours: pathology and genetics: tumours of haematopoietic and lymphoid tissues","author":"Valent","year":"2001"},{"issue":"1","key":"10.1016\/j.iac.2006.05.009_bib129","first-page":"94","article-title":"Splenectomy in the management of systemic mast cell disease","volume":"107","author":"Friedman","year":"1990","journal-title":"Surgery"},{"issue":"2","key":"10.1016\/j.iac.2006.05.009_bib130","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/0016-5085(80)90591-0","article-title":"Portal hypertension associated with systemic mastocytosis and splenomegaly","volume":"78","author":"Grundfest","year":"1980","journal-title":"Gastroenterology"},{"issue":"8","key":"10.1016\/j.iac.2006.05.009_bib131","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1111\/j.1365-2044.1987.tb04112.x","article-title":"Histamine levels and cardiovascular responses during splenectomy and splenorenal shunt formation in a patient with systemic mastocytosis","volume":"42","author":"Smith","year":"1987","journal-title":"Anaesthesia"},{"issue":"9","key":"10.1016\/j.iac.2006.05.009_bib132","doi-asserted-by":"crossref","first-page":"2954","DOI":"10.1182\/blood.V84.9.2954.2954","article-title":"Origin of human mast cells: development from transplanted hematopoietic stem cells after allogeneic bone marrow transplantation","volume":"84","author":"Fodinger","year":"1994","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.iac.2006.05.009_bib133","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1002\/(SICI)1096-8652(199801)57:1<24::AID-AJH4>3.0.CO;2-3","article-title":"Allogeneic marrow transplantation for myeloproliferative disorders other than chronic myelogenous leukemia: review of forty cases","volume":"57","author":"Przepiorka","year":"1998","journal-title":"Am J Hematol"},{"issue":"5","key":"10.1016\/j.iac.2006.05.009_bib134","first-page":"413","article-title":"Persistence of systemic mastocytosis after allogeneic bone marrow transplantation in spite of complete remission of the associated myelodysplastic syndrome","volume":"8","author":"Ronnov-Jessen","year":"1991","journal-title":"Bone Marrow Transplant"},{"issue":"6","key":"10.1016\/j.iac.2006.05.009_bib135","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1038\/sj.bmt.1704627","article-title":"Evidence for a graft-versus-mast-cell effect after allogeneic bone marrow transplantation","volume":"34","author":"Spyridonidis","year":"2004","journal-title":"Bone Marrow Transplant"},{"issue":"4","key":"10.1016\/j.iac.2006.05.009_bib136","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1046\/j.1365-2141.1996.d01-1713.x","article-title":"Graft-versus-leukaemia: understanding and using the alloimmune response to treat haematological malignancies","volume":"93","author":"Barrett","year":"1996","journal-title":"Br J Haematol"},{"issue":"2","key":"10.1016\/j.iac.2006.05.009_bib137","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/S0950-3536(97)80011-X","article-title":"Graft-versus-leukaemia","volume":"10","author":"Barrett","year":"1997","journal-title":"Baillieres Clin Haematol"},{"issue":"4","key":"10.1016\/j.iac.2006.05.009_bib138","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1002\/stem.150248","article-title":"Mechanisms of the graft-versus-leukemia reaction","volume":"15","author":"Barrett","year":"1997","journal-title":"Stem Cells"},{"issue":"1","key":"10.1016\/j.iac.2006.05.009_bib139","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1046\/j.1365-2141.2000.02405.x","article-title":"Non-myeloablative stem cell transplants","volume":"111","author":"Barrett","year":"2000","journal-title":"Br J Haematol"},{"issue":"4","key":"10.1016\/j.iac.2006.05.009_bib140","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/sj.bmt.1705245","article-title":"A pilot study of nonmyeloablative allogeneic hematopoietic stem cell transplant for advanced systemic mastocytosis","volume":"37","author":"Nakamura","year":"2006","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"10.1016\/j.iac.2006.05.009_bib141","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1182\/blood-2004-12-4617","article-title":"Activation mutations of human c-KIT resistant to imatinib mesylate are sensitive to the tyrosine kinase inhibitor PKC412","volume":"106","author":"Growney","year":"2005","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.iac.2006.05.009_bib142","doi-asserted-by":"crossref","first-page":"2865","DOI":"10.1182\/blood-2005-04-1568","article-title":"Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation","volume":"106","author":"Gotlib","year":"2005","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.iac.2006.05.009_bib143","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.ccr.2005.01.020","article-title":"AMN107: tightening the grip of imatinib","volume":"7","author":"O'Hare","year":"2005","journal-title":"Cancer Cells"},{"issue":"9","key":"10.1016\/j.iac.2006.05.009_bib144","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1038\/sj.leu.2403887","article-title":"The systemic mastocytosis-specific activating cKit mutation D816V can be inhibited by the tyrosine kinase inhibitor AMN107","volume":"19","author":"von Bubnoff","year":"2005","journal-title":"Leukemia"},{"key":"10.1016\/j.iac.2006.05.009_bib145","first-page":"10a","volume":"104","author":"Giles","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.iac.2006.05.009_bib146","first-page":"104","article-title":"Overriding imatinib resistance with a novel ABL kinase inhibitor","author":"Shah","year":"2004","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.iac.2006.05.009_bib147","doi-asserted-by":"crossref","first-page":"1a","DOI":"10.1182\/blood.V104.11.1.1","article-title":"Hematologic and cytogenetic responses in imatinib-resistant chronic phase chronic myeloid leukemia patients treated with the dual SRC\/\/ABL kinase inhibitor","volume":"104","author":"Sawyers","year":"2004","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.iac.2006.05.009_bib148","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1182\/blood-2005-10-3969","article-title":"Dasatinib (BMS-354825) inhibits KITD816V, an imatinib-resistant activating mutation that triggers neoplastic growth in the majority of patients with systemic mastocytosis","volume":"108","author":"Shah","year":"2006","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.iac.2006.05.009_bib149","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1158\/0008-5472.CAN-05-2050","article-title":"Dasatinib (BMS-354825), a dual SRC\/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies","volume":"66","author":"Schittenhelm","year":"2006","journal-title":"Cancer Res"},{"issue":"12","key":"10.1016\/j.iac.2006.05.009_bib150","doi-asserted-by":"crossref","first-page":"3754","DOI":"10.1182\/blood-2004-06-2189","article-title":"Sensitivity of oncogenic KIT mutants to the kinase inhibitors MLN518 and PD180970","volume":"104","author":"Corbin","year":"2004","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.iac.2006.05.009_bib151","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1182\/blood-2003-05-1669","article-title":"Effects of MLN518, a dual FLT3 and KIT inhibitor, on normal and malignant hematopoiesis","volume":"104","author":"Griswold","year":"2004","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.iac.2006.05.009_bib152","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1182\/blood-2004-12-4771","article-title":"In vitro and in vivo activity of ATP-based kinase inhibitors AP23464 and AP23848 against activation-loop mutants of Kit","volume":"106","author":"Corbin","year":"2005","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.iac.2006.05.009_bib153","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1182\/blood-2003-07-2477","article-title":"17-Allylamino-17-demethoxygeldanamycin (17-AAG) is effective in down-regulating mutated, constitutively activated KIT protein in human mast cells","volume":"103","author":"Fumo","year":"2004","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.iac.2006.05.009_bib154","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.1182\/blood-2004-08-3247","article-title":"A novel NF-\u03baB inhibitor, IMD-0354, suppresses neoplastic proliferation of human mast cells with constitutively activated c-kit receptors","volume":"105","author":"Tanaka","year":"2005","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.iac.2006.05.009_bib155","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1182\/blood-2005-07-3022","article-title":"PKC412 inhibits in vitro growth of neoplastic human mast cells expressing the D816V-mutated variant of KIT: comparison with AMN107, imatinib, and cladribine (2CdA), and evaluation of cooperative drug effects","volume":"107","author":"Gleixner","year":"2006","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.iac.2006.05.009_bib156","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1159\/000085560","article-title":"Interferon treatment for hypereosinophilic syndromes and systemic mastocytosis","volume":"114","author":"Butterfield","year":"2005","journal-title":"Acta Haematol"},{"issue":"12","key":"10.1016\/j.iac.2006.05.009_bib157","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1007\/s002770000206","article-title":"Effects of interferon-alpha2b treatment on ex vivo differentiation of mast cells from circulating progenitor cells in a patient with systemic mastocytosis","volume":"79","author":"Schernthaner","year":"2000","journal-title":"Ann Hematol"},{"issue":"4","key":"10.1016\/j.iac.2006.05.009_bib158","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1046\/j.1365-2141.2002.03944.x","article-title":"Treatment of adult systemic mastocytosis with interferon-alpha: results of a multicentre phase II trial on 20 patients","volume":"119","author":"Casassus","year":"2002","journal-title":"Br J Haematol"},{"issue":"2","key":"10.1016\/j.iac.2006.05.009_bib159","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/S0145-2126(03)00258-3","article-title":"Cladribine activity in systemic mast cell disease: application of biochemistry in the modern era of molecular biology","volume":"28","author":"Nieva","year":"2004","journal-title":"Leuk Res"},{"issue":"3","key":"10.1016\/j.iac.2006.05.009_bib160","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1182\/blood.V96.3.925","article-title":"Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor","volume":"96","author":"Heinrich","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.iac.2006.05.009_bib161","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2005-04-1568","article-title":"Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation","author":"Gotlib","year":"2005","journal-title":"Blood"}],"container-title":["Immunology and Allergy Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889856106000567?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889856106000567?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,5,10]],"date-time":"2023-05-10T09:49:11Z","timestamp":1683712151000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889856106000567"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,8]]},"references-count":161,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2006,8]]}},"alternative-id":["S0889856106000567"],"URL":"https:\/\/doi.org\/10.1016\/j.iac.2006.05.009","relation":{},"ISSN":["0889-8561"],"issn-type":[{"value":"0889-8561","type":"print"}],"subject":[],"published":{"date-parts":[[2006,8]]}}}